Navigation Links
ESF awards 13th European Latsis Prize to James Vaupel on pioneering demographic research
Date:11/23/2011

Strasbourg -- The European Science Foundation (ESF) has awarded this year's European Latsis Prize to Professor James W. Vaupel, of the Max Planck Institute for Demographic Research in Rostock, Germany. The theme for this year's prize was "Demography." Professor Vaupel was awarded the prize for his contributions to research on ageing and lifespan, and his profound influence on demographic research. The Prize was awarded on the eve of the Annual Assembly of the European Science Foundation, which will take place on 24 November in Strasbourg, France.

The European Latsis Prize, entering its 13th year, is valued at 100,000 Swiss francs (80,000). The Prize is funded by the Geneva-based Latsis Foundation and awarded by the ESF to an individual or a research group who, in the opinion of their peers, has made the greatest contribution to a particular field of European research. The theme "Mathematics" has been chosen for the 2012 Latsis Prize.

"The recognition of my work into demographic research is extremely flattering and I am delighted to be considered for such an esteemed award," commented Vaupel. "This research has been my life work and I am extremely passionate about it. The world is continually changing and demographic changes are quite fascinating. I like to say based on our research that 70 year-olds today are as healthy as 60 year-olds were 50 years ago. We are gaining about two additional years of healthy life every decade."

James Vaupel is honoured for a lifetime of groundbreaking research into the biology of ageing, the statistics of senescence and the connection between public health and longevity. His key papers on mortality and lifespan have each been cited many hundreds of times, and he has been honoured by the Ipsen Foundation in France and twice by the Population Association of America. He is a member of the US National Academy of Sciences and the German National Academy of Sciences Leopoldina. The Latsis Prize announced in the month that the planet's human population reached 7 billion highlights the importance of both the discipline and his contribution to it.

He founded the Max Planck Institute in Rostock in 1996 and turned it into one of the world's leading centres of demographic research. He and colleagues have looked for lessons about the dynamics of ageing going also beyond the human species to see if senescence is a property of all complex systems. But perhaps his most dramatic contribution is in the contention that there seems no looming limit to human lifespan: an argument he put with Jim Oeppen in Science in 2002.

The criteria used in the selection procedure are scientific excellence, societal impact, and contribution to European progress. The nominations were evaluated by a jury of eminent scientists in the field. Sir Roderick Floud, chairman of the jury that selected Professor Vaupel as the winner of this year's prize remarks "Professor Vaupel was chosen because of his seminal contributions to several different fields within demography, his central role in the development of demographic research and training in Europe, and the importance of his work for the understanding of the "grand challenge" of population ageing in Europe."


'/>"/>
Contact: Shira Tabachnikoff, ESF
stabachnikoff@esf.org
33-038-876-7132
European Science Foundation
Source:Eurekalert

Related medicine news :

1. Awards honor UT Dallas researcher and Ph.D. students
2. CDC and Prevention awards Mayo Clinic an international medical education grant
3. FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation
4. USAID awards cooperative agreement to CONRAD for multipurpose prevention study
5. US Army awards $1.5 million for sleep research
6. Georgia Tech researchers receive 3 NSF Emerging Frontiers awards
7. 2 scientists at the University of Texas at Austin receive early career awards from White House
8. US Department of Defense awards University of South Florida $1.59 million for musculoskeletal research
9. University Hospitals Case Medical Center awarded 2011 fellowship awards for pain medicine, epilepsy
10. NCI awards $19.3m for multisite investigation of cancer disparities
11. Elsevier congratulates Dr. Charles Silverstein upon his receipt of 2 awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 22, 2017 , ... “To Walk Away”: a captivating and romantic sequel ... Koontz. “To Walk Away” is the creation of published author, Larry R. Sherman, a ... manuscripts in chemistry and religion, as well as four novels. , Though the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s spiritual ... published author, Julianne Hale, a consultant for the Intelligence Community. For more ... on the Near East region. Julianne has written hundreds of reports for ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... TopConsumerReviews.com recently ... to fight Fatigue . , As the stress of modern life continually makes ... the pace. Constant use of artificial stimulants can trap people in vicious high/low cycles ...
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los ... plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz ... completed residency in Plastic and Reconstructive Surgery. The candidate will have the ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... E.I. Medical Imaging (EIMI) has partnered with ... design the worlds first ultrasound system to be used underwater ... habitat. In preparation for a piece produced by Icon ... Dr. Guttridge approached EIMI with the idea of an underwater ... sharks underwater. EIMI ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 The ... treat rare nervous system diseases, has concluded a worldwide license ... the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing ... in a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology: